Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | BRD4 | O60885 | 8/20 | 0.43 |
| ▸ | BRD2 | P25440 | 2/20 | 0.43 |
| ▸ | STK10 | O94804 | 2/20 | 0.40 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5785912 | 0.90 | RET (0.48) | RETBRD4BRD2 | |
| SCHEMBL7475488 | 0.90 | RET (0.48) | RETBRD4BRD2 | |
| SCHEMBL5783373 | 0.90 | RXFP1 (0.41) | RETBRD4BRD2RXFP1LMNA | |
| SCHEMBL5789109 | 0.88 | RET (0.55) | RETBRD4BRD2SMN1; SMN2 | |
| SCHEMBL5789112 | 0.88 | RET (0.55) | RETBRD4BRD2SMN1; SMN2 | |
| SCHEMBL5787515 | 0.87 | MEN1 (0.41) | BRD4RXFP1SMN1; SMN2 | |
| SCHEMBL7464386 | 0.87 | MEN1 (0.41) | BRD4RXFP1SMN1; SMN2 | |
| SCHEMBL6335847 | 0.84 | RET (0.48) | RETBRD4BRD2STK10SLK | |
| SCHEMBL5782088 | 0.84 | RET (0.48) | RETBRD4BRD2STK10SLK | |
| SCHEMBL6329403 | 0.83 | BRD4 (0.41) | RETBRD4BRD2STK10SLK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212318-B1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | RET 154/4885BRD4 439/4885BRD2 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.